ResearcherUniversity of Colorado AnschutzNo recent work listed

Anna Schreiber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2136-2476; OpenAlex author ID A5020076611. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 1 paper

Papers 1

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Co-author DOI 10.2174/2212697x05666180516120907 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Thea Kalebic · 1 shared paper, 2018 · strength 0.07
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907 ↗
John J. Arcaroli · 1 shared paper, 2018 · strength 0.07
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907 ↗
Todd M. Pitts · 1 shared paper, 2018 · strength 0.07
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907 ↗
Wells A. Messersmith · 1 shared paper, 2018 · strength 0.07
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.